1-4 of 4
Linlin Guo
Close
Sort by
Journal Articles

The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

Luis A. Carvajal, Michael R. McKeown, Tressa Hood, Linlin Guo, Charles Y. Lin, Jorge F. DiMartino
Journal: Blood
Blood (2023) 142 (Supplement 1): 5951.
https://doi.org/10.1182/blood-2023-186605
Published: 2023
Journal Articles

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies

Akanksha Pandey, Luis A. Carvajal, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Tressa Hood, Linlin Guo, Tamara D Hopkins, Nikolaus Obholzer, Michael R. McKeown, Jorge F. DiMartino, Charles Y. Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 2259.
https://doi.org/10.1182/blood-2023-174114
Published: 2023
Journal Articles

HERG K+ Channels Promote Angiogenesis by Enhancing the Expression Level of VEGF in Leukemia Cells in Vitro.

Huiyu Li, Ph.D, Shenghua Jie, Yuan Tian, Shaoyang Gao, Dongmei Guo, Linlin Guo, Shiang Huang
Journal: Blood
Blood (2009) 114 (22): 4818.
https://doi.org/10.1182/blood.V114.22.4818.4818
Published: 2009
Journal Articles

HERG K + Channel Is Essential for Leukemic Cell Migration Induced by SDF-1.

Huiyu Li, Yi-Mei Du, Linlin Guo, Tiannan Guo, Shenghua Jie, Wen Du, Xiangjun Chen, Wei Liu, Jiahua Zhang, Linlin Fan, Anruo Zou, Songyu Zhang, Shiang Huang
Journal: Blood
Blood (2008) 112 (11): 1637.
https://doi.org/10.1182/blood.V112.11.1637.1637
Published: 2008